Evaluation of clinical data in bladder cancer immunotherapy with Connaught BCG (ImmuCyst)

L Barreto1, Z Csizer, J D Sparkes

  • 1Connaught Laboratories Limited, Willowdale, Ontario, Canada.

Developments in Biological Standardization
|January 1, 1992
PubMed

Treatment of superficial bladder carcinoma in situ with Connaught BCG (ImmuCyst) significantly increased complete response rate and extended the disease-free interval when compared with Doxorubicin (DOX) chemotherapy. In 54 patients treated with ImmuCyst, 74% showed complete response compared with 42% of 60 patients treated with DOX. The median disease-free time was 48.2 months for BCG and 5.9 months for DOX treatment. Types and severity of adverse reactions were similar for both treatments and within tolerable ranges.

Related Concept Videos